CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Indication||Adult patients with unresectable or metastatic microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer whose tumours have progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as monotherapy.|
|Review Status||Not Filed|
|Manufacturer||Merck Canada Inc.|
|Clarification||CADTH is unable to recommend reimbursement because a submission was not filed by the manufacturer.|
|Last Updated||February 25, 2020|